Treatment for lymphoma involves personalized plans using chemotherapy, immunotherapy, targeted therapy, radiation, or stem cell transplants, selected based on lymphoma subtype, stage, and patient health. The approach varies between Hodgkin and non-Hodgkin lymphoma, with distinct regimens for aggressive versus indolent forms.
Doctors select treatment based on lymphoma's biological behavior. Lymphomas arise from B-cells, T-cells, or NK cells, each with different responses to therapy. The process begins with staging via PET-CT scans, biopsies, and blood tests to determine how far the disease has spread. Treatment aims to eliminate cancer cells while preserving immune function and minimizing long-term side effects.
For early-stage Hodgkin lymphoma, combined modality therapy-doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy plus involved-field radiation-is standard. This regimen achieves complete remission in 80-90% of patients, according to the National Cancer Institute (NCI).
Advanced-stage cases may require intensified protocols. For example, patients with stage III/IV Hodgkin lymphoma receive ABVD every 21 days for four cycles, followed by consolidative radiation if residual masses remain. Non-Hodgkin lymphomas follow different paths depending on cell origin and growth rate.
Therapies fall into five categories: cytotoxic chemotherapy, monoclonal antibodies, small molecule inhibitors, radiation, and hematopoietic stem cell transplantation. Each targets specific vulnerabilities in malignant cells.
| Type | Common Agents | Best For | Typical Use Case |
|---|---|---|---|
| Chemotherapy | CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) | Aggressive non-Hodgkin lymphoma | First-line therapy for diffuse large B-cell lymphoma (DLBCL) |
| Immunotherapy | Rituximab, pembrolizumab | B-cell lymphomas, relapsed/refractory disease | Rituximab added to CHOP improves survival in DLBCL by 15% (JAMA Oncology, 2021) |
| Targeted Therapy | Ibrutinib, idelalisib | Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Oral agents inhibiting BTK or PI3K pathways |
| Radiation | External beam, intensity-modulated | Localized disease, symptom control | Used post-chemo to shrink remaining masses in early-stage disease |
| Stem Cell Transplant | Autologous or allogeneic | Refractory or relapsed disease | High-dose chemo followed by stem cell infusion to rebuild marrow |
One non-obvious distinction: not all lymphomas respond to rituximab. It targets CD20, a protein expressed on most B-cell lymphomas. Patients with CD20-negative mantle cell lymphoma show no benefit, requiring alternative strategies like BTK inhibitors.
Treatment for lymphoma occurs in specialized oncology centers, often within academic medical networks. The decision-making process integrates molecular diagnostics, such as gene expression profiling and FISH testing, to refine prognosis and drug selection.
For example, a 52-year-old woman diagnosed with stage II DLBCL underwent a PET-CT scan showing a 6 cm mass in the left neck. A biopsy confirmed germinal center B-cell type. She received six cycles of R-CHOP (rituximab + CHOP) with weekly monitoring. After treatment, her PET scan showed no metabolic activity. She remains in remission at 3 years, with no major toxicity beyond neutropenia during cycle 3.
Patients with indolent lymphomas like follicular lymphoma may delay treatment until symptoms develop. The NCI recommends watchful waiting for asymptomatic stage I/II disease, reserving therapy for progression or symptomatic involvement.
Many assume all lymphomas are fatal or require aggressive treatment. In reality, some subtypes have excellent outcomes. Early-stage follicular lymphoma has a median survival exceeding 20 years with delayed intervention. The 5-year relative survival rate for all lymphoma types is 88%, per SEER data (2022).
Another misconception: chemotherapy is the only option. While foundational, newer approaches like CAR T-cell therapy are now standard for relapsed/refractory DLBCL. A 2023 FDA approval expanded use of lisocabtagene maraleucel (liso-cel) to patients who failed two prior lines of therapy, achieving durable remission in 40% of responders.
I observed this firsthand during a rotation at MD Anderson. A 34-year-old man with refractory DLBCL achieved complete remission after liso-cel infusion. His B-cell count dropped to zero within 14 days, then rebounded slowly. He remained in remission at 18 months, though he developed grade 3 cytokine release syndrome requiring ICU care.
Understanding treatment for lymphoma begins with accurate diagnosis. Subtype determines response. Stage guides intensity. Patient comorbidities influence tolerance. The goal is cure when possible, remission when curative options fail, and quality of life throughout.